Skip to main content
SpringerLink
Log in

The author replies

  • Correspondence
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Frampton JE, Faulds D. Filgrastim: a reappraisal of pharmacoeconomic considerations in the prophylaxis and treatment of chemotherapy-induced neutropenia. PharmacoEconomics 1996; 9: 76–96

    Article  PubMed  CAS  Google Scholar 

  2. Glaspy J. Economic effect of myeloid growth factors on cancer treatment. Clin Immunother 1994 Sep; 2: 233–9

    Article  Google Scholar 

  3. Riikonen P, Rahiala J, Salonvaara M, et al. Prophylactic administration of granulocyte colony-stimulating factor (filgrastim) after conventional chemotherapy in children with cancer. Stem Cells 1995; 13:289–94

    Article  PubMed  CAS  Google Scholar 

  4. Eguchi K, Sasaki S, Tamura T, et al. Dose escalation study of recombinant human granulocyte-colony stimulating factor (KRN8601) in patients with advanced malignancy. Cancer Res 1989; 49: 5221–4

    PubMed  CAS  Google Scholar 

  5. Ohnoshi T, Ueoka H, Kodain T, et al. Effect of recombinant human granulocyte colony-stimulating factor (rG-CSF) on chemotherapy-induced neutropenia in patients with lung cancer. Gan To Kagaku Ryoho 1990; 17: 911–8

    PubMed  CAS  Google Scholar 

  6. Yoshida T, Nakamura S, Ohtake S, et al. Effect of granulocyte colony-stimulating factor on neutropenia due to chemotherapy for non-Hodgkin’s lymphoma. Cancer 1990; 66: 1904–9

    Article  PubMed  CAS  Google Scholar 

  7. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. Clin Infect Dis 1994 Feb; 18 Suppl. 2: 189–96

    Article  Google Scholar 

  8. Pettengell R, Gurney H, Radford JA, et al. Granulocyte colony stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin’s lymphoma: a randomized controlled trial. Blood 1992; 80: 1430–6

    PubMed  CAS  Google Scholar 

  9. Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1992; 29A: 319–24

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, Auckland, New Zealand

    Diana Faulds

Authors
  1. Diana Faulds
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Faulds, D. The author replies. Pharmacoeconomics 9, 467–468 (1996). https://doi.org/10.2165/00019053-199609050-00010

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199609050-00010

Keywords

Search

Navigation